A carregar...
High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
BACKGROUND: Glioblastoma multiforme (GBM) is a rare and deadly disease, with a reported average incidence rate of 3.19 cases per 100,000 inhabitants. Fotemustine, a third-generation nitrosourea with an alanine phosphor carrier that facilitates cellular penetration, has been extensively investigated...
Na minha lista:
| Publicado no: | Medicine (Baltimore) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wolters Kluwer Health
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076126/ https://ncbi.nlm.nih.gov/pubmed/29979390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000011254 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|